obesity drug news today glp-1 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 New studies find that GLP-1

In vitro , liraglutide dose-dependently downregulates pro-inflammatory mediators such as Mcp-1 and Cd38 in LPS-activated RAW264.7 macrophages, while simultaneously upregulating Erg-2, an M2-specific transcription factor (Yu et al., 2019)

At $149/month for the starting dose, oral Wegovy through WeightWatchers is not only the most affordable FDA-approved option on this list, its actually cheaper than several compounded injectable programs

Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials

Abstract Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejection fraction (HFpEF), it reduced weight, lowered blood pressure, and improved outcomes

Patients also receive guidance on the Bariatric Surgery procedure and follow-up support

To increase the stability of GLP-1R, the fusion protein rubredoxin was inserted into intracellular loop 2 (ICL2) of GLP-1R between positions 257 to 262 and 11 mutations were introduced